切换至 "中华医学电子期刊资源库"
高级检索
中华肾病研究电子杂志

中华肾病研究电子杂志 ›› 2024, Vol. 13 ›› Issue (02) : 97 -100. doi: 10.3877/cma.j.issn.2095-3216.2024.02.007

综述

慢性肾脏病患者接种新型冠状病毒疫苗有效力及接种策略的研究进展
张今宜1, 李月红2,†()   
  1. 1. 102218　北京，清华大学医学院
    2. 102218　北京清华长庚医院肾内科
  • 收稿日期:2023-03-27 出版日期:2024-04-28
  • 通信作者: 李月红
  • 基金资助:
    首都临床特色应用研究(Z181100001718129); 北京市医院管理中心临床医学发展专项经费(YGLX202332)

Research progress on the efficacy and strategy of SARS-CoV-2 vaccination in patients with chronic kidney disease

Jinyi Zhang1, Yuehong Li2,†()   

  1. 1. Tsinghua University School of Medicine
    2. Department of Nephrology, Beijing Tsinghua Changgeng Hospital; Beijing 102218, China
  • Received:2023-03-27 Published:2024-04-28
  • Corresponding author: Yuehong Li
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张今宜, 李月红. 慢性肾脏病患者接种新型冠状病毒疫苗有效力及接种策略的研究进展[J]. 中华肾病研究电子杂志, 2024, 13(02): 97-100.

Jinyi Zhang, Yuehong Li. Research progress on the efficacy and strategy of SARS-CoV-2 vaccination in patients with chronic kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 97-100.

慢性肾脏病尤其是终末期肾病接受肾脏替代治疗的患者，在新型冠状病毒感染疫情中面临巨大风险。研究显示，慢性肾脏病患者接种现有的新冠疫苗安全性较高，且全程接种能使大多数慢性肾脏病患者产生特异性抗体。但疫苗在慢性肾脏病患者中产生的体液反应和效力均显著弱于健康人群。增加疫苗接种剂次和采用混合接种对提高疫苗在慢性肾脏病患者中的保护效力具有潜在价值，但相关的接种策略仍值得进一步研究。本文综述了慢性肾脏病患者接种新冠疫苗的可行性、安全性、有效力及针对性接种策略方面的研究进展。

关键词: 慢性肾脏疾病, 终末期肾病, 透析, 新型冠状病毒, 疫苗接种

Patients with chronic kidney disease, especially end-stage renal disease, who are receiving renal replacement therapy, are at great risk in the epidemic of COVID-19. Studies have shown that the existing COVID-19 vaccines are safe for patients with chronic kidney disease, and the whole course of vaccination can produce specific antibodies in most patients with chronic kidney disease. However, the humoral response and efficacy of the vaccines in patients with chronic kidney disease were significantly weaker than in healthy people. Increase of the number of vaccinations and use of combined vaccinations may have potential value in improving the protective efficacy of the vaccines in patients with chronic kidney disease, but the relevant vaccination strategies still need to be further studied. This paper reviewed the research progress on the feasibility, safety, efficacy, and targeted vaccination strategies of the SARS-CoV-2 vaccination for patients with chronic kidney disease.

Key words: Chronic kidney disease, COVID-19, SARS-CoV-2, Vaccination
[1]
Russo AG, Decarli A, Valsecchi MG. Strategy to identify priority groups for COVID-19 vaccination: a population based cohort study [J]. Vaccine, 2021, 39(18): 2517-2525.
[2]
Glenn DA, Hegde A, Kotzen E, et al. Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease [J]. Kidney Int Rep, 2021, 6(5): 1407-1410.
[3]
Krueger KM, Ison MG, Ghossein C. Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation [J]. Am J Kidney Dis, 2020, 75(3): 417-425.
[4]
Longlune N, Nogier MB, Miedouge M, et al. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients [J]. Nephrol Dial Transplant, 2021, 36(9): 1704-1709.
[5]
Park JS, Minn D, Hong S, et al. Immunogenicity of COVID-19 vaccination in patients with end-stage renal disease undergoing maintenance hemodialysis: the efficacy of a mix-and-match strategy [J]. J Korean Med Sci, 2022, 37(23): e180.
[6]
Attias P, Sakhi H, Rieu P, et al. Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients [J]. Kidney Int, 2021, 99(6): 1490-1492.
[7]
Grupper A, Sharon N, Finn T, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis [J]. Clin J Am Soc Nephrol, 2021, 16(7): 1037-1042.
[8]
Speer C, Goth D, Benning L, et al. Early humoral responses of hemodialysis patients after COVID-19 vaccination with BNT162b2 [J]. Clin J Am Soc Nephrol, 2021, 16(7): 1073-1082.
[9]
Torreggiani M, Blanchi S, Fois A, et al. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won [J]. Kidney Int, 2021, 99(6): 1494-1496.
[10]
Kolb T, Fischer S, Muller L, et al. Impaired immune response to SARS-CoV-2 vaccination in dialysis patients and in kidney transplant recipients [J]. Kidney360, 2021, 2(9): 1491-1498.
[11]
Goupil R, Benlarbi M, Beaubien-Souligny W, et al. Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis [J]. CMAJ, 2021, 193(22): E793-E800.
[12]
Yau K, Abe KT, Naimark D, et al. Evaluation of the SARS-CoV-2 antibody response to the BNT162b2 vaccine in patients undergoing hemodialysis [J]. JAMA Netw Open, 2021, 4(9): e2123622.
[13]
Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant [J]. Transplantation, 2022, 106(4): 821-834.
[14]
Billany RE, Selvaskandan H, Adenwalla SF, et al. Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms [J]. Kidney Int, 2021, 99(6): 1492-1494.
[15]
Brunelli SM, Sibbel S, Karpinski S, et al. Comparative effectiveness of mRNA-based BNT162b2 vaccine versus adenovirus vector-based Ad26.COV2.S vaccine for the prevention of COVID-19 among dialysis patients [J]. J Am Soc Nephrol, 2022, 33(4): 688-697.
[16]
Zhang YM, Liu XZ, Lin MM, et al. Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients [J]. J Infect, 2022, 85(2): 174-211.
[17]
Li H, Cai D, Jiang D, et al. Risk of waning humoral responses after inactivated or subunit recombinant SARS-CoV-2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China [J]. J Med Virol, 2023, 95(1): e28434.
[18]
Sibbel S, Mckeon K, Luo J, et al. Real-world effectiveness and immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients on hemodialysis [J]. J Am Soc Nephrol, 2022, 33(1): 49-57.
[19]
Oliver MJ, Thomas D, Balamchi S, et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes in the maintenance dialysis population in ontario, canada [J]. J Am Soc Nephrol, 2022, 33(4): 839-849.
[20]
Ashby DR, Caplin B, Corbett RW, et al. Severity of COVID-19 after vaccination among hemodialysis patients: an observational cohort study [J]. Clin J Am Soc Nephrol, 2022, 17(6): 843-850.
[21]
Torres R, Toro L, Sanhueza ME, et al. Clinical efficacy of SARS-CoV-2 vaccination in hemodialysis patients [J]. Kidney Int Rep, 2022, 7(10): 2176-2185.
[22]
Karoui K, Hourmant M, Ayav C, et al. Vaccination and COVID-19 dynamics in dialysis patients [J]. Clin J Am Soc Nephrol, 2022, 17(3): 395-402.
[23]
Hernandez-Porto M, Garcia S, Delgado T, et al. Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis [J]. Int J Infect Dis, 2022, 122: 327-331.
[24]
Attias P, Azzaoui I, Karoui K, et al. Immune responses after a third dose of mRNA vaccine differ in virus-naive versus SARS-CoV-2- recovered dialysis patients [J]. Clin J Am Soc Nephrol, 2022, 17(7): 1008-1016.
[25]
Kanai D, Wakui H, Haze T, et al. Improved immune response to the third COVID-19 mRNA vaccine dose in hemodialysis patients [J]. Kidney Int Rep, 2022, 7(12): 2718-2721.
[26]
Garcia P, Han J, Montez-Rath ME, et al. SARS-CoV-2 booster vaccine response among patients receiving dialysis [J]. Clin J Am Soc Nephrol, 2022, 17(7): 1036-1038.
[27]
Montez-Rath ME, Garcia P, Han J, et al. SARS-CoV-2 infection during the omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies and vaccine doses [J]. J Am Soc Nephrol, 2022, 33(10): 1832-1839.
[28]
Einbinder Y, Perl J, Nacasch N, et al. Humoral response and SARS-CoV-2 infection risk following the third and fourth doses of the BNT162b2 vaccine in dialysis patients [J]. Am J Nephrol, 2022, 53(7): 586-590.
[29]
Housset P, Kubab S, Hanafi L, et al. Humoral response after a fourth "booster" dose of a coronavirus disease 2019 vaccine following a 3-dose regimen of mRNA-based vaccination in dialysis patients [J]. Kidney Int, 2022, 101(6): 1289-1290.
[30]
Anft M, Blazquez-Navarro A, Frahnert M, et al. Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses [J]. Kidney Int, 2022, 102(1): 207-208.
[31]
Ovcar E, Patyna S, Kohmer N, et al. Increasing but insufficient neutralizing activity against Omicron-BA.1 after a second booster dose of mRNA-1273 vaccine in chronic haemodialysis patients [J]. Clin Kidney J, 2022, 15(12): 2346-2348.
[32]
Kim DK, Jung SW, Moon JY, et al. Severe acute respiratory syndrome coronavirus 2 antibody response after heterologous immunizations with ChAdOx1/BNT162b2 in end-stage renal disease patients on hemodialysis [J]. Front Immunol, 2022, 13: 894700.
[33]
Mrak D, Sieghart D, Simader E, et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial [J]. Nat Commun, 2022, 13(1): 5362.
[34]
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine [J]. N Engl J Med, 2021, 384(5): 403-416.
[35]
张金铭，张治伦. 终末期肾病血液透析患者接种新冠病毒灭活疫苗的临床研究[J]. 中国社区医师，2022, 38(35): 57-59.
[36]
于海波，王立华，王喆，等. 维持性血液透析患者接种新型冠状病毒肺炎疫苗的安全性及影响因素[J]. 中华肾脏病杂志，2023, 39(2): 112-118.
[37]
Tan HZ, Tan RY, Choo JC, et al. Is COVID-19 vaccination unmasking glomerulonephritis? [J]. Kidney Int, 2021, 100(2): 469-471.
[38]
D′agati VD, Kudose S, Bomback AS, et al. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine [J]. Kidney Int, 2021, 100(2): 461-465.
[39]
Gondor G, Ksiazek SH, Regele H, et al. Development of crescentic membranoproliferative glomerulonephritis after COVID-19 vaccination [J]. Clin Kidney J, 2022, 15(12): 2340-2342.
[40]
Kervella D, Jacquemont L, Chapelet-Debout A, et al. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine [J]. Kidney Int, 2021, 100(2): 457-458.
[41]
Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy [J]. Kidney Int, 2021, 99(6): 1487.
[42]
Komaba H, Wada T, Fukagawa M. Relapse of minimal change disease following the Pfizer-BioNTech COVID-19 vaccine [J]. Am J Kidney Dis, 2021, 78(3): 469-470.
[43]
Aydin MF, Yildiz A, Oruc A, et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination [J]. Kidney Int, 2021, 100(2): 464-465.
[1] 唐博, 罗季平, 周桃, 黄多, 刘廷琼, 陈亚萍, 岳文胜. 慢性肾衰竭血液透析患者造瘘侧上肢肱动脉-指端微小动脉血流动力学变化特点分析[J]. 中华医学超声杂志（电子版）, 2023, 20(12): 1276-1281.
[2] 钱雅君, 虞竹溪, 徐颖, 董丹江, 顾勤. 危重型新型冠状病毒感染合并侵袭性肺曲霉病的临床特征和高危因素分析[J]. 中华危重症医学杂志(电子版), 2024, 17(01): 3-9.
[3] 马丽洁, 赵素梅, 孙芳, 孙倩美. 平均血小板体积和平均血小板体积/血小板计数比值对血液透析患者血管通路失功的潜在预测价值[J]. 中华肾病研究电子杂志, 2024, 13(02): 61-67.
[4] 唐全兴, 周畅. 维持性血液透析患者血清suPAR对动静脉内瘘狭窄发生的诊断价值[J]. 中华肾病研究电子杂志, 2024, 13(02): 74-78.
[5] 冯娟, 詹伟强. 维持性血液透析患者血清热休克蛋白70及簇集蛋白水平与主要不良心血管事件的相关性[J]. 中华肾病研究电子杂志, 2024, 13(01): 34-38.
[6] 兰洁, 薛福平, 任娇娇, 廖智菲, 焦原野, 李静, 王利华. 维持性血液透析患者的住院情况及其影响因素分析[J]. 中华肾病研究电子杂志, 2023, 12(06): 301-307.
[7] 刘键, 张晓娜, 徐宏娟, 彭丽敏, 宋晶晶. 环硅酸锆钠对血液透析患者营养状态的影响：前瞻性巢式病例对照研究[J]. 中华肾病研究电子杂志, 2023, 12(06): 308-313.
[8] 杨洁, 王红叶, 张蕊. 低温透析模式预防透析中低血压的效果Meta分析[J]. 中华肾病研究电子杂志, 2023, 12(06): 314-322.
[9] 王晶晶, 谢晖, 邓璞钰, 张晨晨, 田学, 谢云, 王瑞兰. 新型冠状病毒感染ARDS患者EIT监测下俯卧位通气成像的改变[J]. 中华重症医学电子杂志, 2024, 10(01): 31-37.
[10] 刘付蓉, 翁利, 杜斌. 2020年至2022年中国重症医学临床研究进展[J]. 中华重症医学电子杂志, 2024, 10(01): 48-53.
[11] 李浩南, 张煜彭, 付焱, 冯继伟, 刘凯, 张文凯. 缝隙连接蛋白43在肺部疾病中的研究进展[J]. 中华重症医学电子杂志, 2024, 10(01): 60-65.
[12] 倪世豪, 董晓明, 刘浩辉, 何星灵, 刘东华, 李姿儒, 李思静, 姜艳辉, 黄婕, 张小娇, 鲁路, 杨忠奇. 治疗新型冠状病毒感染中成药的临床证据分析[J]. 中华临床医师杂志(电子版), 2023, 17(12): 1253-1269.
[13] 蒲蕾, 冯韵霖, 洪大情, 何强, 李贵森, 陈瑾. 蛋白质-能量消耗对血液透析患者预后的影响[J]. 中华临床医师杂志(电子版), 2023, 17(10): 1051-1057.
[14] 赵伟, 李晓帆, 赵海丹. 维持性血液透析患者血尿酸等代谢指标的纵向数据分析[J]. 中华临床医师杂志(电子版), 2023, 17(10): 1064-1070.
[15] 葛静萍, 尹媛媛, 李燕. 梯度压力袜联合间歇充气加压在老年新型冠状病毒肺炎患者预防下肢深静脉血栓形成中的应用[J]. 中华介入放射学电子杂志, 2024, 12(01): 70-74.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号